Skip to main content Back to Top


Tirofiban Hydrochloride Injection

Products Affected - Description

    • Aggrastat intravenous injection, Medicure Pharma, 50 mcg/mL, 5 mg/100 mL vial, 1 count, NDC 25208-0002-03

Reason for the Shortage

    • Medicure Pharma has Aggrastat on shortage due to an interruption at their third-party manufacturing site.

Available Products

    • Aggrastat intravenous injection, Medicure Pharma, 250 mcg/mL, 3.75 mg/15 mL bolus vial, 1 count, NDC 25208-0001-04
    • Aggrastat intravenous injection, Medicure Pharma, 50 mcg/mL, 12.5 mg/250 mL premixed bag, 1 count, NDC 25208-0002-02

Estimated Resupply Dates

    • Medicure Pharma has Aggrastat 5 mg/mL 100 mL premixed vials on back order and the company estimates a release date of fall 2019.


Updated July 9, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 13, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins